Compared with that in healthy controls, AML patients showed reduced levels of the NK-activating receptors NKG2D, NKp46, and NKp30 in their peripheral blood, while there was an upregulation in the expression of inhibitory receptors such as TIM-3, ILT-4, ILT-5, and PD-1. Here, KLRK1 is linked to acute myeloid leukemia.